Developmentally regulated and thalamus-selective induction of leiomodin2 gene by a schizophrenomimetic, phencyclidine, in the rat

International Journal of Neuropsychopharmacology

Volumn 12, Issue 8, 2009, Pages 1111-1126

  Takebayashi, Hironao ^a   Yamamoto, Naoki ^a   Umino, Asami ^a   Nishikawa, Toru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Leiomodin2 gene (Lmod2); Phencyclidine; Postnatal development; Schizophrenia; Thalamus

Indexed keywords

DIZOCILPINE; HALOPERIDOL; MESSENGER RNA; METHAMPHETAMINE; PHENCYCLIDINE; TROPOMYOSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE INDUCTION; GENOME; HEART; HEART MUSCLE; IN SITU HYBRIDIZATION; LEIOMODIN2 GENE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERINATAL PERIOD; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SKELETAL MUSCLE; THALAMUS; UPREGULATION;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; CYTOSKELETAL PROTEINS; DIZOCILPINE MALEATE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HALLUCINOGENS; HALOPERIDOL; MALE; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MYOCARDIUM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENCYCLIDINE; RATS; RATS, WISTAR; RNA, MESSENGER; THALAMUS; TIME FACTORS; TROPOMODULIN;

EID: 69749118943     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709009997     Document Type: Article

References (59)

1. Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Boles Ponto LL, Hichwa RD (1997). Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-näive patients. Lancet 349, 1730-1734.
2. Andrews J, Wang L, Csernansky JG, Gado MH, Barch DM (2006). Abnormalities of thalamic activation and cognition in schizophrenia. American Journal Psychiatry 163, 463-469.
3. Bruneau EG, McCullumsmith RE, Haroutunian V, Davis KL, Meador-Woodruff JH (2005). Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophrenia Research 75, 27-34.
4. Buchanan RW, Carpenter Jr. W.T. (2005). Concept of schizophrenia. In: Sadock BJ, Sadock VA (Eds), Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 8th edn (pp. 1329-1345). Baltimore: Lippincott Williams & Wilkins.
5. Buxbaum JD, Georgieva L, Young JJ, Plescia C, Kajiwara Y, Jiang Y, Moskvina V, Norton N, Peirce T, Williams H, et al. (2008). Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene. Molecular Psychiatry 13, 162-172.
6. Carlisle HJ, Kennedy MB (2005). Spine architecture and synaptic plasticity. Trends in Neuroscience 28, 182-187.
7. Clinton SM, Meador-Woodruff JH (2004). Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophrenia Research 69, 237-253.
8. Conley CA, Fritz-Six KL, Almenar-Queralt A, Fowler VM (2001). Leiomodins: larger members of the tropomodulin (Tmod) gene family. Genomics 73, 127-139.
9. Dragunow M, Faull RL (1990). MK-801 induces c-fos protein in thalamic and neocortical neurons of rat brain. Neuroscience Letters 111, 39-45. (Pubitemid 20102115)
10. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA (1999). Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Research 843, 171-183.
11. Dundr M, Ospina JK, Sung MH, John S, Upender M, Ried T, Hager GL, Matera AG (2007). Actin-dependent intranuclear repositioning of an active gene locus in vivo. Journal Cell Biology 179, 1095-1103.
12. Fischer RS, Fowler VM (2003). Tropomodulins: life at the slow end. Trends in Cell Biology 13, 593-601.
13. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA (2005). Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38, 301-311.
14. Greifenstein FE, Devault M, Yoshitake J, Gajewski JE (1958). A study of a 1-aryl cyclo hexyl amine for anesthesia. Anesthesia and Analgesia 37, 283-294.
15. Ibrahim HM, Hogg Jr. A.J., Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH (2000). Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. American Journal Psychiatry 157, 1811-1823.
16. Ito T, Hiraoka S, Kuroda Y, Ishii S, Umino A, Kashiwa A, Yamamoto N, Kurumaji A, Nishikawa T (2007). Effects of schizophrenomimetics on the expression of the CCN1 (CYR 61) gene encoding a matricellular protein in the infant and adult neocortex of the mouse and rat. International Journal of Neuropsychopharmacology 10, 717-725.
17. Jakary A, Vinogradov S, Feiwell R, Deicken RF (2005). N-acetylaspartate reductions in the mediodorsal and anterior thalamus in men with schizophrenia verified by tissue volume corrected proton MRSI. Schizophrenia Research 76, 173-185.
18. Javitt DC (2004). Glutamate as a therapeutic target in psychiatric disorders. Molecular Psychiatry 9, 984-997, 979.
19. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 148, 1301-1308.
20. Kaiser S, Foltz LA, George CA, Kirkwood SC, Bemis KG, Lin X, Gelbert LM, Nisenbaum LK (2004). Phencyclidine-induced changes in rat cortical gene expression identified by microarray analysis: implications for schizophrenia. Neurobiolgy of Disease 16, 220-235.
21. Kong KY, Kedes L (2004). Cytoplasmic nuclear transfer of the actin-capping protein tropomodulin. Journal of Biological Chemistry 279, 30856-30864.
22. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001). Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25, 455-467.
23. Langsjö JW, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V, Sipilä H, Kurki T, Silvanto M, Scheinin H (2003). Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 99, 614-623.
24. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA (2008). Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neuroscience 31, 234-242.
25. MAQC Consortium (2006). The MicroArray Quality Control (MAQC) project shows inter- and intraplatformreproducibility of gene expression measurements. Nature Biotechnology 24, 1151-1161.
26. McClung CA, Nestler EJ (2003). Regulation of gene expression and cocaine reward by CREB and Delta-FosB. Nature Neuroscience 6, 1208-1215.
27. Miyasaka M, Domino EF (1968). Neural mechanisms of ketamine-induced anesthesia. International Journal of Neuropharmacology 7, 557-573.
28. Morgan JI, Curran T (1991). Stimulus-transcription coupling in the nervous system: involvement of inducible proto-oncogenes fos and jun. Annual Review of Neuroscience 14, 421-451.
29. Nakai K, Horton P (1999). PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends in Biochemical Sciences 24, 34-36.
30. Nagata K, Kiryu-Seo S, Kiyama H (2006). Localization and ontogeny of damage-induced neuronal endopeptidase mRNA-expressing neurons in the rat nervous system. Neuroscience 141, 299-310.
31. Nishikawa T, Kajii Y, Hiraoka S, Fujiyama K, Sato D, Toda S, Kaneda K, Umino A, Kuroda Y (1998). A molecular pharmacological approach to neural dysfunction in schizophrenia. Neuroscience Research (Suppl.) 22, S8.
32. Nishikawa T, Umino A, Tanii Y, Hashimoto A, Hata N, Takashima M, Takahashi K, Toru M (1991). Dysfunction of excitatory amino acidergic systems and schizophrenic disorders. In: Nakazawa T (Ed.), Biological Basis of Schizophrenic Disorders (pp. 65-76). Tokyo: Japan Scientific Societies Press. Basel: Karger.
33. Ohba N, Kiryu-Seo S, Maeda M, Muraoka M, Ishii M, Kiyama H (2004). Expression of damage-induced neuronal endopeptidase (DINE) mRNA in peri-infarct cortical and thalamic neurons following middle cerebral artery occlusion. Journal of Neurochemistry 91, 956-964.
34. Palacios JM, Wamsley JK, Kuhar MJ (1981). High affinity GABA receptors-autoradiographic localization. Brain Research 222, 285-307.
35. Pérez-Navarro E, Alberch J, Marsal J (1993). Postnatal development of functional dopamine, opioid and tachykinin receptors that regulate acetylcholine release from rat neostriatal slices. Effect of 6-hydroxydopamine lesion. International Journal of Developmental Neuroscience 11, 701-708.
36. Petersen RC, Stillman RC (1978). Phencyclidine (PCP) Abuse: An Appraisal. National Institute on Drug Abuse Research Monograph series, Superintendent of Documents, US Government Printing Office: Washington, DC.
37. Reich DL, Silvay G (1989). Ketamine: an update on the first twenty-five years of clinical experience. Canadian Journal of Anaesthesia 36, 186-197.
38. Rose SE, Chalk JB, Janke AL, Strudwick MW, Windus LC, Hannah DE, McGrath JJ, Pantelis C, Wood SJ, Mowry BJ (2006). Evidence of altered prefrontal-thalamic circuitry in schizophrenia: an optimized diffusion MRI study. Neuroimage 32, 16-22.
39. Sakurai S, Ishii S, Umino A, Shimazu D, Yamamoto N, Nishikawa T (2004). Effects of psychotomimetic and antipsychotic agents on neocortical and striatal concentrations of various amino acids in the rat. Journal of Neurochemistry 90, 1378-1388.
40. Sanjuán J, Tolosa A, González JC, Aguilar EJ, Pérez-Tur J, Nájera C, Moltó MD, de Frutos R (2006). Association between FOXP2 polymorphisms and schizophrenia with auditory hallucinations. Psychiatry Genetics 16, 67-72.
41. Sato D, Umino A, Kaneda K, Takigawa M, Nishikawa T (1997). Developmental changes in distribution patterns of phencyclidine-induced c-Fos in rat forebrain. Neuroscience Letters 239, 21-24.
42. Scalzo FM, Burge LJ (1994). The role of NMDA and sigma systems in the behavioral effects of phencyclidine in preweanling rats. Neurotoxicology 15, 191-200.
43. Scalzo FM, Holson RR (1992). The ontogeny of behavioral sensitization to phencyclidine. Neurotoxicology and Teratology 14, 7-14.
44. Schwartz RH, Einhorn A (1986). PCP intoxication in seven young children. Pediatric Emergency Care 2, 238-241.
45. Segura I, Essmann CL, Weinges S, Acker-Palmer A (2007). Grb4 and GIT1 transduce ephrinB reverse signals modulating spine morphogenesis and synapse formation. Nature Neuroscience 10, 301-310.
46. Shintomi K (1975). Effects of psychotropic drugs on methamphetamine- induced behavioral excitation in grouped mice. Europen Journal of Pharmacology 31, 195-206.
47. Shirayama Y, Mitsushio H, Takahashi K, Nishikawa T (2000). Differential effects of haloperidol on phencyclidine-induced reduction in substance P contents in rat brain regions. Synapse 35, 292-299.
48. Sim K, Cullen T, Ongur D, Heckers S (2006). Testing models of thalamic dysfunction in schizophrenia using neuroimaging. Journal of Neural Transmission 113, 907-928.
49. Sturgeon RD, Fessler RG, Meltzer HY (1979). Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. European Journal of Pharmacology 59, 169-179.
50. Takahashi H, Higuchi M, Suhara T (2006). The role of extrastriatal dopamine D2 receptors in schizophrenia. Biological Psychiatry 59, 919-928.
51. Tanabe K, Kiryu-Seo S, Nakamura T, Mori N, Tsujino H, Ochi T, Kiyama H (1998). Alternative expression of Shc family members in nerve-injured motoneurons. Brain Research Molecular Brain Research 53, 291-296. (Pubitemid 28085465)
52. Tanabe K, Nakagomi S, Kiryu-Seo S, Namikawa K, Imai Y, Ochi T, Tohyama M, Kiyama H (1999). Expressed-sequence-tag approach to identify differentially expressed genes following peripheral nerve axotomy. Brain Research Molecular Brain Research 64, 34-40.
53. Tanii Y, Nishikawa T, Hashimoto A, Takahashi K (1994). Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. Journal of Pharmacology and Experimental Therapeutics 269, 1040-1048.
54. Umino A, Takahashi K, Nishikawa T (1998). Characterization of the phencyclidine-induced increase in prefrontal cortical dopamine metabolism in the rat. British Journal of Pharmacology 124, 377-385.
55. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J (1997). Differential psychopathology and patterns of cerebral glucose utilization produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). European Neuropsychopharmacology 7, 25-38.
56. Watis L, Chen SH, Chua HC, Chong SA, Sim K (2008). Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review. Journal of Neural Transmission 115, 493-511.
57. Watanabe M, Inoue Y, Sakimura K, Mishina M (1992). Developmental changes in distribution of NMDA recepto channel subunit mRNAs. Neuroreport 3, 1138-1140.
58. Welch MJ, Correa GA (1980). PCP intoxication in young children and infants. Clinical Pediatrics (Philadelphia) 19, 510-514.
59. White PF, Way WL, Trevor AJ (1982). Ketamine - its pharmacology and therapeutic uses. Anesthesiology 56, 119-136.